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Abstract: Cholangiocarcinoma (CCA) comprises a group of heterogeneous biliary cancers with 
dismal prognosis. The etiologies of most CCAs are unknown, but primary sclerosing cholangitis 
(PSC) is a risk factor. Non-invasive diagnosis of CCA is challenging and accurate biomarkers are 
lacking. We aimed to characterize the transcriptomic profile of serum and urine extracellular 
vesicles (EVs) from patients with CCA, PSC, ulcerative colitis (UC), and healthy individuals. Serum 
and urine EVs were isolated by serial ultracentrifugations and characterized by nanoparticle 
tracking analysis, transmission electron microscopy, and immunoblotting. EVs transcriptome was 
determined by Illumina gene expression array [messenger RNAs (mRNA) and non-coding RNAs 
(ncRNAs)]. Differential RNA profiles were found in serum and urine EVs from patients with CCA 
compared to control groups (disease and healthy), showing high diagnostic capacity. The 
comparison of the mRNA profiles of serum or urine EVs from patients with CCA with the 
transcriptome of tumor tissues from two cohorts of patients, CCA cells in vitro, and CCA cells-
derived EVs, identified 105 and 39 commonly-altered transcripts, respectively. Gene ontology 
analysis indicated that most commonly-altered mRNAs participate in carcinogenic steps. Overall, 
patients with CCA present specific RNA profiles in EVs mirroring the tumor, and constituting novel 
promising liquid biopsy biomarkers. 
Keywords: biomarkers; cholangiocarcinoma; extracellular vesicles; liquid biopsy; transcriptomics 
 
1. Introduction 
Cholangiocarcinomas (CCAs) are heterogeneous biliary malignancies characterized by dismal 
prognosis. The incidence and mortality rates of these cancers are rapidly increasing globally, 
currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies 
[1–3]. According to their anatomical localization, CCAs are classified into intrahepatic (iCCA), 
perihilar (pCCA), or distal (dCCA). The etiology of most CCAs is unknown. However, several risk 
factors have been described, including the presence of primary sclerosing cholangitis (PSC: 5–15% 
develops CCA), a chronic cholestatic liver disease that is associated with autoimmune phenomena 
against the intra- and extrahepatic bile ducts [1,4,5]. Importantly, 70–80% of patients with PSC 
concomitantly present inflammatory bowel disease (IBD), mainly ulcerative colitis (UC), which is 
thought to precede the development of the liver disease [4]. 
CCAs are generally asymptomatic in early stages, being therefore commonly diagnosed in 
advanced phases when the disease is disseminated. Late diagnosis combined with the chemoresistant 
nature of these tumors [6] highly compromise the current therapeutic options, mainly based on 
surgery, significantly impacting on patient’s welfare and outcome [1,2]. The diagnosis of CCA is 
usually conducted by combining clinical, biochemical, radiological, and histological information. 
Imaging techniques usually rely on computed tomography (CT), magnetic resonance imaging (MRI), 
magnetic resonance cholangiopancreatography (MRCP), positron emission tomography (PET), 
percutaneous transhepatic cholangiography (PTC), endoscopic retrograde 
cholangiopancreatography (ERCP), or endoscopic ultrasound depending on the tumor location 
[1,5,7]. However, imaging proceedings have important limitations, as they are not accurate enough 
to determine the malignity of the tumor masses, particularly in early stages, as well as to differentiate 
between the main primary liver cancers, i.e., iCCA, hepatocellular carcinoma (HCC) or HCC-CCA 
mixed tumors, which is fundamental to provide the appropriate standards of care. On the other hand, 
MRCP and histological analysis (biopsy or brushing cytology) comprise the major diagnostic tools 
for PSC [4,8,9]. In addition, the measurement of non-specific serum tumor biomarkers [i.e., 
carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA)] is commonly conducted 
in order to help in the diagnosis of CCA, but their low sensitivity (particularly in early stages of the 
disease) and specificity (also elevated in some PSC patients without cancer), raise important concerns 
regarding their clinical utility [7,10]. Therefore, tumor biopsy is currently mandatory to confirm the 
diagnosis and staging of CCA, guiding the clinical management of these patients [11]. Based on all of 
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these diagnostic concerns, there is an urgent need to determine new accurate, non-invasive 
biomarkers for the early diagnosis of CCA, particularly in patients at risk. 
In the last decade, extracellular vesicles (EVs) have been envisioned as promising tools in the 
quest for tumor biomarkers and as important mediators of disease pathogenesis [12]. EVs constitute 
a heterogeneous population of lipid bilayered spheres (30 nm – 2 μm in diameter) containing diverse 
biomolecules (e.g., proteins, nucleic acids, lipids, and metabolites), which are released by cells and 
found in all biofluids (e.g., blood and urine) [13,14]. Taking into account their biogenesis, EVs may 
be classified as exosomes, microvesicles (MV), and apoptotic bodies. These small vesicles participate 
in cell-to-cell communications, modulating signaling pathways in pathobiology [13–17]. We 
previously reported a differential proteomic profile of serum EVs from patients with CCA, HCC, or 
PSC, as well as from healthy individuals, identifying accurate candidate biomarkers for the 
differential diagnosis of these diseases [18]. Considering that tumor cells can also release RNAs 
encapsulated within EVs, and that their profiles can mimic the cellular state/alterations, an extensive 
characterization of the RNA content from serum and urine EVs from patients with CCA (and control 
conditions) might provide new diagnostic biomarkers as well as therapeutic targets. 
In this study, we aimed to characterize the RNA profile of serum and urine EVs from patients 
with CCA, PSC, or UC, as well as healthy individuals, and identify candidate diagnostic biomarkers 
mirroring their tumor cell expression within the liquid biopsy concept. For this purpose, the 
expression of selected candidates was evaluated in human CCA tumor and surrounding healthy 
tissues from two independent cohorts of patients [The Cancer Genome Atlas (TCGA) and 
Copenhagen], as well as in cell cultures (CCA vs. normal) and EVs released by normal or tumor 
human cholangiocytes in vitro. 
2. Materials and Methods 
2.1. Patients 
Serum and urine samples from patients with CCA (n = 12 and 23, respectively), PSC (n = 6 and 
5, respectively), UC (n = 8 and 12, respectively), and healthy individuals (n = 9 and 5, respectively) 
were obtained from Donostia University Hospital (San Sebastian, Spain), Cruces University Hospital 
(Bilbao, Spain), and “Complejo Hospitalario de Navarra” (Pamplona, Spain). The Ethical Committees 
for Clinical Research from each participating institution approved all the research protocols and all 
patients accepted to participate in the study and signed the written consents to allow the use of their 
samples for biomedical research. Clinical characteristics of patients and tumors are summarized in 
Supplementary Table 1. The diagnosis of PSC was based on the European Association for the Study 
of the Liver (EASL) guidelines [19] by demonstrating the presence of bile duct alterations (strictures 
or irregularities in intrahepatic and extrahepatic bile ducts) using MRCP after excluding secondary 
causes of cholangitis. The diagnosis of UC was performed by combining endoscopic and histological 
studies, mainly colonoscopy in parallel with hematoxylin and eosin (H&E) staining, after excluding 
other potential diseases. Finally, CCA diagnosis was confirmed by histological analysis of tumor 
samples and/or through the combination of clinical, biochemical and radiological approaches. Tumor 
stage was determined based on the 7th edition of the American Joint Committee on Cancer (AJCC) 
classification. 
RNA-seq data from the TCGA cohort (36 CCAs and 9 surrounding liver samples) [20], 
downloaded as level 3 data through FireBrowse portal [BROAD Institute of MIT & Harvard, MA, 
USA (source: https://gdac.broadinstitute.org/)], and whole transcriptome profiling [Human 
Transcriptome (HT) BeadChips (Illumina Inc., San Diego, CA, USA)] of the “Copenhagen cohort” 
including 217 CCA surgical specimens (153 iCCA, 43 pCCA, 15 dCCA, 6 unknown location), 143 
normal surrounding liver samples, and 9 normal intrahepatic bile ducts (GSE26566) [21,22] were used 
to evaluate the expression of serum and urine biomarkers in tumor tissue. 
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2.2. Cell Cultures 
Normal human cholangiocytes (NHCs) were isolated from normal liver tissue and characterized 
as previously described [23–25]. Furthermore, two commercial human CCA cell lines (EGI1 and 
TFK1, Leibniz Institute DSMZ-German Collection of Microoganism and Cell Cultures, Germany) 
were used. NHC and EGI1 cells were cultured in fully-supplemented DMEM/F-12 medium, as 
previously described [23–25], while TFK1 cells were cultured in DMEM/F-12 supplemented with 10% 
fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 1% 
penicillin/streptomycin (P/S; Gibco). Cells were seeded in 150 mm collagen-coated tissue culture 
dishes (4 × 106 cells) with each respective cell culture medium and left for plate attachment overnight. 
Afterwards, cells were washed with phosphate-buffered saline (PBS) and incubated with “EV 
recollection media” (DMEM/F-12+Glutamax supplemented with 1% P/S, and without serum). After 
48 h, cells were harvested for RNA isolation and cell culture media was collected and stored at −80 
°C for subsequent EVs isolation. Cells were grown at 37 °C in a humidified chamber of 5% CO2. 
During all the experiments, mycoplasm test was performed by conventional PCR and cells were 
tested as mycoplasm negative. 
2.3. Isolation of EVs from Serum, Urine, and Cell Cultures 
Serum, urine, and cell-derived EVs were isolated as previously described [18]. Briefly, 1 mL of 
serum, 50 mL of urine, or 300 mL of cell culture media (frozen at −80 °C) were thawed at room 
temperature and further processed through serial differential ultracentrifugation steps at 4 °C. First, 
in order to remove cell debris, serum, urine and cell culture media were centrifuged at 10,000× g for 
30 min and subsequently ultracentrifuged at 100,000× g for 75 min, to pellet the EVs, which were then 
washed with PBS and pelleted again after ultracentrifugation at 100,000× g for 75 min. Finally, the 
pelleted EV fraction was resuspended in 20 μL of PBS and then stored at −80 °C for further analysis. 
2.4. Transmission Electron Microscopy (TEM) 
For the characterization of EVs, the isolated fraction of EVs was stained negatively and analyzed 
by TEM. EV samples were directly adsorbed onto glow-discharged (60 seg low discharging using a 
PELCO easy-glow device) carbon-coated copper grid (300 mesh). Afterwards, grids were fixed with 
2% paraformaldehyde (PFA) in phosphate buffer (PB 0.2M pH 7.4) for 20 min and washed with 
distilled water. Then, the contrast staining was made by incubating the grids with 4% uranyl acetate 
(UA) at 4 °C for 15 min. TEM images were obtained by using TECNAI G2 20 C-TWIN high-resolution 
transmission electron microscope, at an acceleration voltage of 200 kV. 
2.5. Immunoblotting 
Protein levels of both EV and endoplasmic reticulum markers (i.e., CD63 and CD81 vs. GRP78, 
respectively) were evaluated in serum and urine EVs and in whole-cell extracts (WCEs) by 
immunobloting. Total protein concentration was calculated with the Micro BCA protein assay kit 
(Thermo Fisher Scientific,), following the manufacturer’s instructions. Loading buffer [50 mM Tris-
HCl, 2% SDS, 10% glycerol and 0.1% bromophenol blue, without β-mercaptoethanol or dithiothreitol 
(DTT)] was added to protein samples, followed by heat denaturation at 95 °C for 5 min. Then, 10 and 
4 μg of total protein from serum and urine EVs, respectively, were separated by 12.5% sodium 
dodecyl sulfate-polyacrilamide gel electrophoresis (SDS-PAGE) and electro-transferred onto a 
nitrocellulose membrane (GE Healthcare, Chicago, IL, USA) and blocked with 5% skim milk 
powder/tris-buffered saline (TBS)-0.1% tween (TBS-Tween) for 1 h. Afterwards, membranes were 
probed overnight at 4°C with the appropriate primary antibodies [anti-CD81 (BD Biosciences), anti-
CD63 (DSHB), and anti-GRP78 (BD Biosciences, San Jose, CA, USA)] at 1:500 dilution in blocking 
solution and, after three washes with TBS-Tween (5 min each), horseradish peroxidase-conjugated 
secondary antibody (anti-mouse; Cell Signaling, Danvers, MA, USA) at a dilution of 1:5000 (in milk 
blocking solution) were incubated for 1 h at room temperature. Membranes were developed for 
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protein detection using ECL plus (Thermo Fisher Scientific), with the iBright FL1500 Western Blot 
Imaging System (Thermo Fisher Scientific). 
2.6. EV Size and Concentration 
Size distribution and concentration of EVs were evaluated by nanoparticle tracking analysis 
(NTA) using a NanoSight LM10 System (Malvern, UK) further equipped with fast video capture and 
a particle-tracking software. NTA post-acquisition settings were kept constant for all samples. Each 
video was analyzed for obtaining the mean and mode vesicle size as well as particle concentration. 
2.7. Total RNA Isolation 
After EVs isolation, total RNA was extracted using the miRCURY™ RNA Isolation Kit (Qiagen, 
Hilden, Germany) following manufacturer’s specifications. Afterwards, total RNA was resuspended 
in 20 μL of distilled H2O and later used for transcriptomic analysis. Regarding cell samples, total 
RNA was extracted using the TRIzol®  reagent according to the manufacturer’s instructions (Life 
Technologies Corp., Carlsbad, CA, USA). 
2.8. Illumina Gene Expression Array 
Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchips were used to characterize gene 
expression [messenger RNAs (mRNAs) and non-coding RNAs (ncRNAs)]. The quality of RNA 
samples was measured using a RNA Pico Chip Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). 200 ng of RNA samples were used for the array. The cDNA synthesis, prequalification, 
amplification, labeling and hybridization of the samples were performed following the WG-DASL 
HT Assay Lab protocol (Illumina Inc.). The amplified cDNAs were hybridized to the diverse gene-
probes of the array and gene expression levels were detected by a HiScan scanner (Illumina Inc.). 
Raw data were extracted with GenomeStudio analysis software (Illumina Inc.), in the form of 
GenomeStudio’s Final Report. Raw expression data were background-corrected, log2-transformed 
and quantile-normalized using the lumi R package [26] (Bioconductor repository, Chicago, IL, USA). 
To perform the Venn diagrams, all the transcripts identified in at least one sample with a “detection 
p-value” < 0.01 were selected. Afterwards, in the comparisons between groups, transcripts that were 
significantly identified in at least 20% of the samples (with a bilateral p-value < 0.05; independent 
samples two-tailed t-test, not assuming equal variances) were considered for subsequent analysis. 
2.9. Functional Enrichment Analysis 
Functional analysis of candidate liquid biopsy RNA biomarkers was determined by gene 
ontology (GO) enrichment of biological processes, molecular pathways and functions, by using the 
Functional Enrichment analysis tool (FunRich) version 3.1.3 (Funrich Industrial Co. Ltd, Hong 
Kong)[27,28]. 
2.10. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 6.0 (GraphPad Software, San 
Diego, CA, USA). Data are shown as boxes and whiskers (min to max). When comparing two groups, 
non-parametric Mann-Whitney or parametric t-Student tests were conducted. For comparisons 
between more than two groups, non-parametric Kruskal-Wallis test followed by a posteriori Dunns 
test of the parametric one-way analysis of variance (ANOVA) test followed by a posteriori Tukey’s 
post hoc test were used. In order to calculate the diagnostic values of serum and urine RNA 
biomarkers, allowing to discriminate between patients with CCA, PSC and UC, and healthy 
individuals, area under the receiver operating characteristic curve (AUC) values were determined 
using the SPSS 20.0 software (IBM, Ehningen, Germany), followed by the calculation of sensitivity 
(SEN) and specificity (SPE) values, positive predictive value (PPV), negative predictive value (NPV), 
positive likelihood ratio (PLR), negative likelihood ratio (NLR), and accuracy index (AI). Differences 
were considered significant when p < 0.05.  
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3. Results 
3.1. Characterization of Serum and Urine EVs from Patients with CCA, PSC, or UC, and Healthy 
Individuals 
After isolation, serum and urine EVs were characterized by TEM, immunoblotting and NTA. In 
resemblance with our previous findings using the same isolation protocol [18], TEM images showed 
a typical rounded morphology in the isolated vesicles from both serum and urine (~100–200 nm), 
corresponding to exosomes and/or small microvesicles (Figure 1A). By immunoblotting, the EV 
protein markers CD63 and CD81 were highly enriched in the isolated EV fraction, when compared 
to total serum or NHC whole-cell extracts (WCE), while the endoplasmic reticulum marker 78 kDa 
glucose-regulated protein (GRP78) was completely absent in isolated serum and urine EVs but only 
found expressed in WCE from NHCs (Figure 1B), substantiating a proper isolation and a high purity 
of the obtained EVs. Regarding the size of EVs, NTA revealed no significant differences in the size of 
serum and urine EVs among groups, presenting an average size of ~180 nm, in resemblance with 
serum and urine EV concentration, which was found similar in the study population (Figure 1C). 
Cells 2020, 9, 721 7 of 38 
 
 
Figure 1. Characterization of serum and urine EVs from patients with CCA, PSC, UC, and healthy 
controls. In order to validate the protocol for EVs isolation, we used blood serum and urine from 
healthy individuals. (A) TEM images of blood serum (left) and urine (right) EVs from healthy 
individuals showcasing the typical round shape (~150 nm) and morphology. (B) Representative 
immunoblots of the EV markers CD63 and CD81 (positive controls) and GRP78 (negative control) 
from EVs isolated from serum (left) and urine (right) of healthy individuals that indicate an 
enrichment of EV markers and a complete absence of the endoplasmic reticulum (ER) marker GRP78, 
compared to total serum and whole cell extracts (WCEs) of normal human cholangiocytes (NHC). (C) 
Nanoparticle tracking analysis (NTA) of serum (up) and urine (down) EVs revealing no differences 
in EV concentration between CCA, PSC, UC, and healthy individuals and a similar EV mode (~180 
nm). 
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3.2. Differential RNA Profiles of Serum EVs from CCA, PSC, UC, and Healthy Individuals 
The transcriptomic profiles of serum and urine EVs isolated from patients with CCA, PSC, UC, 
and healthy controls were determined by RNA microarray-based transcriptomics (Illumina Inc.). 
Transcriptomic data are available in GSE144521. Considering all the transcripts that were identified 
in at least one sample included in any of the study groups (detection p-value < 0.01), a total of 25,084 
transcripts were identified in serum EVs. Among them, 10,104 transcripts were identified in serum 
EVs isolated from healthy individuals, in parallel with the identification of 11,124, 4204, and 24,264 
transcripts in serum EVs from patients with UC, PSC, and CCA, respectively, with 1617 of the 
identified transcripts being shared among all groups (Figure 2A). In all the study groups, the great 
majority of the identified transcripts were mRNAs (9516, 10,526, 3949, and 23,029 transcripts found 
in healthy individuals and patients with UC, PSC, or CCA, respectively), followed by non-coding 
RNAs such as non-coding RNAs (mainly including pseudogenes, long non-coding RNAs (lncRNAs), 
among others), microRNAs (miRNAs or miRs), and small nucleolar RNAs (snoRNAs) (Figure 2B; 
Supplementary Table 2). Other types of RNAs, including small nuclear, miscellaneous, guide, small 
cytoplasmic, antisense, RNase MRP, ribosomal, and telomerase RNAs were also detected. Next, the 
transcriptome of serum EVs from the four study groups was determined and compared. Specifically, 
1932 transcripts were differentially identified in CCA vs. healthy individuals, 2888 in CCA vs. PSC, 
and 2807 in CCA vs. “PSC, UC, and healthy individuals” combined as one unique control (disease 
and healthy) group (Figure 3). Meanwhile, 866 transcripts were differentially identified in serum EVs 
from patients with PSC compared with a group comprised of patients with UC and healthy 
individuals (Supplementary Figure 1). 
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Figure 2. Comparative transcriptomic analysis of serum EVs from patients with CCA, PSC, or UC, 
and healthy individuals. (A) Venn diagrams showing the number of transcripts identified per group. 
Venn diagrams were generated using InteractiVenn web-based tool [29]. (B) Number of transcripts 
identified within each study group, subclassified according to their type [messenger RNA (mRNA), 
non-coding RNA (including mostly pseudogenes and long non-coding RNAs, among others), 
miscelaneous RNA (miscRNA), guide RNA, microRNA (miRNA), small nucleolar RNA (snoRNA), 
small nuclear RNA (snRNA), ribosomal RNA, telomerase RNA, small cytoplasmic RNA, antisense 
RNA and RNase MRP RNA]. In all groups, mRNAs constitute the most abundantly identified RNAs, 
followed by non-coding RNAs (pseudogenes, lncRNAs, and others), miRNAs, and snoRNAs. 
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Figure 3. Differential transcriptomic profile of serum EVs and diagnostic capacity. Volcano plot 
(−log10(p-value) and log2(fold-change); up left), heatmap of the differentially expressed transcripts (up 
right) and diagrams with the diagnostic capacity with the highest AUC values of the 10 selected 
mRNAs and 5 selected non-coding RNAs in serum EVs from (A) CCA vs. Healthy individuals; (B) 
CCA vs. PSC; (C) CCA vs. (PSC + UC + Healthy individuals). Abbreviations: AI, accuracy index; AUC, 
area under the receiver operating characteristic curve; CI, confidence interval; lncRNA, long non-
coding RNA; miRNA, microRNA; NLR, negative likelihood ratio; NPV, negative predictive value; 
PLR, positive likelihood ratio; PPV, positive predictive value; SEN, sensitivity; snoRNA, small 
nucleolar RNA; SPE, specificity. 
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The analysis of candidate RNA biomarkers in serum EVs from CCA vs. healthy individuals 
pointed out ring finger and FYVE like domain containing E3 ubiquitin protein ligase (RFFL), olfactory 
receptor family 4 subfamily F member 3 (OR4F3), and the family with sequence similarity 107 
member B (FAM107B) as the mRNAs with the highest diagnostic capacity, presenting AUC values of 
1.00, 1.00, and 0.991, respectively, along with the non-coding RNAs PMS1 homolog 2 mismatch repair 
system component pseudogene 4 (PMS2L4), miR-604, and SNORA58 (AUC: 0.991, 0.944, and 0.926, 
respectively) (Figure 3A). Since PSC is a well-known risk factor that increases the odds of developing 
CCA, the transcriptomic profiles of serum EVs from patients with CCA vs. PSC were also compared. 
In particular, the mRNA transcripts paraoxonase 1 (PON1), activating transcription factor 4 (ATF4), 
and phosphoglycerate dehydrogenase (PHGDH) stood out as the best candidate biomarkers for the 
differential diagnosis of CCA and PSC, all with AUC values of 1.00 (Figure 3B). Similarly, the 
lncRNAs metastasis associated lung adenocarcinoma transcript 1 (MALAT1) and LOC100190986, 
and the snoRNA SNORA11B (AUCs: 1.00) also presented a high accuracy for the identification of 
CCA vs. PSC (Figure 3B). Of note, several mRNA and non-coding RNAs provided excellent 
diagnostic values (AUC values up to 0.931 and 0.902, respectively) for the diagnosis of PSC, when 
compared with patients with UC and healthy individuals (Supplementary Figure 1). Finally, general 
CCA transcript biomarkers (compared to PSC, UC and healthy individuals combined as one unique 
control group) were also identified and RFFL, zinc finger protein 266 (ZNF266) and OR4F3 
constituted the mRNA transcripts with the highest AUC values (1.00, 0.976, and 0.960, respectively) 
while miR-551B, PMS2L4, and LOC643955 were the ncRNAs presenting the highest diagnostic 
capacity, displaying AUC values of 0.909, 0.880, and 0.873, respectively (Figure 3C). 
3.3. Selective mRNAs Present in Serum EVs from Patients with CCA Mirror their Levels in Human Tumor 
Tissue, CCA Cells in Vitro and EVs-Derived from Tumor Cholangiocytes 
After identifying 2807 transcripts significantly altered in serum EVs from patients with CCA 
compared to patients with PSC, UC, and healthy individuals, we evaluated if the expression of these 
transcripts were also significantly changed in human CCA tissue, compared to non-tumor 
surrounding tissue, in two independent international cohorts of patients (TCGA and the 
“Copenhagen” cohorts). Importantly, 901 out of the 2807 selective RNA transcripts were also altered 
in the TCGA cohort, presenting the same trend of expression when compared to serum EVs, with 765 
transcripts being upregulated while 136 transcripts were downregulated in comparison to non-tumor 
tissue (Figure 4A, left). These 765 transcripts were then cross-validated in the Copenhagen cohort, in 
which we were able to identify 479 shared transcripts with the same expression tendency, with 391 
being upregulated and 88 reduced when compared with surrounding liver tissue (Figure 4A, right). 
After selecting the common mRNAs that share the same trend of expression in serum EVs and tumor 
tissue of patients with CCA compared to controls, we next evaluated their expression levels in two 
human CCA cell lines (EGI1 and TFK1) compared to NHCs in vitro, obtaining 156 commonly altered 
transcripts (Figure 4B). Finally, we isolated EVs from these two CCA cell lines and from NHCs and, 
after their characterization (Supplementary Figure 2) [18], we evaluated their transcriptomic content 
and cross-validated the previous candidate transcripts, resulting in 105 mRNAs with shared altered 
levels in serum EVs, tumor tissue, CCA cell lines, and in CCA-derived EVs (Figure 4C). 
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Figure 4. mRNAs commonly deregulated between serum EVs, CCA tumors from two independent 
cohorts of patients, tumor cells in vitro and in CCA-derived EVs. mRNAs differentially abundant in 
serum EVs from patients with CCA vs. (PSC + UC + Healthy individuals) were compared with the 
transcriptome of: (i) patients with CCA from TCGA (n = 36) and “Copenhagen” (n = 217) cohorts, (ii) 
CCA cells (EGI1 and TFK1) and cell-derived EVs compared to their respective control groups, further 
selecting the ones that are commonly expressed. Heatmap of the differentially expressed transcripts 
in (A) TCGA (left) and “Copenhagen” cohorts (right); (B) Whole-cell extracts from CCA cells and 
NHCs; (C) Cell-derived EVs; (D) Gene ontology (GO: FunRich database [27]) analysis of the 105 
transcripts commonly altered in serum EVs, CCA human tumors, CCA cells and in cell-derived EVs, 
highlighting the biological processes and pathways in which the identified transcripts are involved, 
as well as their biological function. Abbreviations: CCA, cholangiocarcinoma, EVs, extracellular 
vesicles; NHCs, normal human cholangiocytes; SL, surrounding liver; TCGA, The cancer genome 
atlas. 
Gene ontology (GO) analysis revealed that the 105 mRNAs previously identified code for 
proteins mainly involved in pivotal processes during carcinogenesis. Specifically, metabolic 
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pathways (nucleic acid and protein metabolism), cell communication, signal transduction, energy, 
and cell growth/maintenance pathways constituted the most represented biological processes in 
which the identified mRNA transcripts are involved, therefore impacting in important cancer-
promoting pathways, such as cell cycle regulation, mitosis, epithelial-mesenchymal transition (EMT), 
DNA repair, and telomere maintenance (Figure 4D). Of note, the expression of some of these 
transcripts positively correlated with worse disease severity (i.e., advanced tumor stage and tumor 
dedifferentiation) in the TCGA and Copenhagen cohorts (Supplementary Figure 3). Among all the 
105 transcripts identified, c-Maf inducing protein (CMIP), glutamate decarboxylase 1 (GAD1), nucleoside 
diphosphate kinase 1 (NME1), CDP-diacylglycerol synthase 1 (CDS1), and cyclin-dependent kinases 
regulatory subunit 1 (CKS1B) constituted the best liquid biopsy candidate biomarkers, as their levels 
were increased in serum EVs and presented AUC values of 0.957, 0.928, 0.899, 0.893, and 0.891, 
respectively, for the diagnosis of CCA in comparison with patients with PSC, UC, and healthy 
individuals grouped together (Figure 5A–E). Importantly, a panel comprised of CMIP, NME1 and 
CKS1B provided the maximum diagnostic capacity (AUC: 1.000) for CCA in comparison with the 
group containing healthy individuals and patients with PSC and UC (Figure 5F). The mRNA levels 
of the aforementioned transcripts were also markedly increased in serum EVs from patients with 
CCA compared with the ones isolated from PSC patients, therefore potentially constituting novel 
biomarkers for the differential diagnosis of CCA and PSC. The mRNA expression levels of these 
genes were also increased in CCA tumor samples from the TCGA and Copenhagen cohorts, 
compared with either normal surrounding liver tissue or normal intrahepatic bile ducts, being also 
found upregulated in CCA tumor cells, compared to NHCs, and also in CCA-derived EVs (Figure 
5A–E). Noteworthy, besides providing the best diagnostic value among all the liquid biopsy 
candidates, CMIP mRNA levels were found particularly increased in poorly-differentiated tumors in 
the Copenhagen cohort (Supplementary Figure 3A). 
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Figure 5. Selected liquid biopsy biomarkers for CCA. From the 105 mRNAs commonly altered in 
serum EVs, CCA human tumors, CCA cells and in cell-derived EVs compared to their corresponding 
controls, 5 biomarkers were selected based on their diagnostic capacity. Box plot diagrams with the 
mRNAs abundance in serum EVs (left), CCA tumors from the TCGA, and “Copenhagen” cohorts, 
CCA cells and cell-derived EVs (right), compared to their respective controls, for (A) c-Maf inducing 
protein (CMIP), (B) glutamate decarboxylase 1 (GAD1), and (C) NME/NM23 nucleoside diphosphate kinase 
1 (NME1); (D) CDP-diacylglycerol synthase 1 (CDS1), and (E) CDC28 protein kinase regulatory subunit 1B 
(CKS1B). (F) Diagnostic prediction (ROC curves and AUC values) of the selected serum liquid biopsy 
biomarkers and for the combination of CMIP, NME1 and CKS1B for the diagnosis of CCA in 
comparison with (PSC + UC + Healthy individuals). Abbreviations: AUC, area under the receiver 
operating characteristic (ROC) curve; EVs, extracellular vesicles; NHC, normal human cholangiocyte; 
NBD, normal bile ducts; SL, surrounding liver; TCGA, The cancer genome atlas. 
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3.4. Differential Transcriptomic Profiles of Urine EVs from Patients with CCA, PSC, UC, and Healthy 
Individuals 
In urine EVs, a total of 11,323, 23,920, 22,159, and 26,066 RNAs were identified in healthy 
individuals and patients with UC, PSC, or CCA, respectively, accounting for a total of 27,319 
transcripts detected (Figure 6A). Regarding the type of transcripts found, similar distribution was 
observed when compared with the profile obtained in serum EVs, abundantly detecting mRNAs, 
followed by ncRNAs such as pseudogenes and lncRNAs, miRNAs, and snoRNAs (Figure 6B). The 
analysis of urine EVs revealed differential transcriptomic profiles between patients with CCA, PSC, 
or UC, and healthy individuals. In particular, 2386 transcripts were differentially identified in urine 
EVs from patients with CCA vs. healthy individuals, 1999 in CCA vs. PSC, and 1329 in CCA vs. other 
diseases (PSC and UC) and healthy individuals combined in a single group. In this regard, INO80 
complex subunit D (INO80D), MAP6 domain containing 1 (MAP6D1) and Ras-related GTP binding D 
(RRAGD) constituted the most promising mRNA biomarkers in urine EVs isolated from patients with 
CCA, in comparison with healthy individuals, displaying AUC values of 1.000. Of note, the lncRNA 
HLA complex group 4 (HCG4), miR200c, and the lncRNA LOC100134868 also presented high accuracies 
for the diagnosis of CCA, with AUC values of 0.930, 0.904, and 0.896, respectively (Figure 7A). 
Regarding the differential identification of CCA and PSC, the mRNA transcripts CAP-Gly domain 
containing linker protein 3 (CLIP3), Vascular cell adhesion molecule 1 (VCAM1) and Tripartite motif 
containing 33 (TRIM33) displayed excellent AUC values (0.965), in parallel with the pseudogene ATP 
synthase F1 subunit epsilon pseudogene 2 (ATP5EP2), the lncRNA LOC100134713, and the Small nucleolar 
RNA, H/ACA box 8 (SNORA8) (AUC: 0.939, 0.930, and 0.922, respectively), thus allowing to 
distinguish patients with CCA and PSC with high sensitivity and specificity values (Figure 7B). When 
comparing urine EVs from patients with PSC vs. UC and healthy individuals considered as a unique 
group, several mRNA and non-coding RNAs arose as potential biomarkers for the diagnosis of PSC, 
with AUC values up to 1.000 and 0.965, respectively (Supplementary Figure 4). Finally, by comparing 
CCA to the group containing patients with other diseases (PSC and UC) and healthy individuals, the 
mRNA metallothionein 1F (MT1F), glutathione peroxidase 3 (GPX3), and lactate dehydrogenase 4 (LDH4) 
stood out as the ones with the best AUC values (0.915, 0.897, and 0.894, respectively), along with the 
ncRNAs U11 small nuclear (RNU11), LOC257358, and vault RNA 1-1 (VTRNA1-1) (0.830, 0.812, and 
0.777, respectively) (Figure 7C), therefore constituting promising urine EV biomarkers for the 
accurate diagnosis of CCA. 
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Figure 6. Comparative transcriptomic analysis of urine EVs from patients with CCA, PSC, or UC, and 
healthy individuals. (A) Venn diagrams showing the number of transcripts identified per group. Venn 
diagrams were generated using InteractiVenn web-based tool [29]. (B) Number of transcripts 
identified within each study group, subclassified according to their type [messenger RNA (mRNA), 
non-coding RNA (including mostly pseudogenes and long non-coding RNAs, among others), 
miscelaneous RNA (miscRNA), guide RNA, microRNA (miRNA), small nucleolar RNA (snoRNA), 
small nuclear RNA (snRNA), ribosomal RNA, telomerase RNA, small cytoplasmic RNA, antisense 
RNA and RNase MRP RNA]. In all groups, mRNAs constitute the most abundantly identified RNAs, 
followed by non-coding RNAs (pseudogenes, lncRNAs, and others), miRNAs, and snoRNAs. 
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Figure 7. Differential transcriptomic profile of urine EVs and diagnostic capacity. Volcano plot 
(−log10(p-value) and log2(fold-change); up left), heatmap of the differentially expressed transcripts (up 
right) and diagrams with the diagnostic capacity with the highest AUC values of the 10 selected 
mRNAs and 5 selected non-coding RNAs in serum EVs from (A) CCA vs. Healthy individuals; (B) 
CCA vs. PSC; (C) CCA vs. (PSC + UC + Healthy individuals). Abbreviations: AI, accuracy index; AUC, 
area under the receiver operating characteristic curve; CI, confidence interval; miRNA, microRNA; 
lncRNA, long non-coding RNA; miscRNA, miscellaneous RNA; NLR, negative likelihood ratio; NPV, 
negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value; SEN, 
sensitivity; snRNA, small nuclear RNA; snoRNA, small nucleolar RNA; SPE, specificity; vtRNA, vault 
RNA. 
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3.5. Selective mRNAs Present in Urine EVs from Patients with CCA Mimic their Levels in Human Tumor 
Tissue, CCA Cells in Vitro, and EVs-Derived from Tumor Cholangiocytes 
Similar to our previous analysis on the serum EV biomarkers identified in patients with CCA, 
compared to all the other study groups, we now selected the 1329 RNA transcripts that were 
significantly altered in urine EVs from patients with CCA and compared their expression levels with 
CCA and surrounding tumor tissues from both TCGA and Copenhagen cohorts. After performing a 
comprehensive analysis of these mRNAs in the TCGA cohort, we were able to identify 390 
dysregulated transcripts (305 upregulated and 85 downregulated) that are commonly altered in urine 
EVs and in tumor samples from patients with CCA (Figure 8A, left). Additionally, compared to the 
changes observed in urine EVs, 259 transcripts also shared the same pattern of alteration in the 
Copenhagen cohort, with 206 transcripts presenting increased expression while 53 transcripts were 
reduced, when compared with surrounding liver (Figure 8A, right). The comparison of these 259 
transcripts with the differential transcriptome of CCA cell lines compared to NHCs, revealed 84 
shared mRNAs that were altered in CCA cells, with 69 being upregulated and 15 displaying 
decreased expression (Figure 8B). In EVs isolated from CCA and NHC cell cultures, we were able to 
identify 39 mRNAs (34 upregulated and 5 downregulated) commonly altered with urine EVs, tumor 
tissue, and CCA cells (Figure 8C). 
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Figure 8. mRNAs commonly deregulated between urine EVs, CCA tumors from two independent 
cohorts of patients, tumor cells in vitro and in CCA-derived EVs. mRNAs differentially abundant in 
serum EVs from patients with CCA vs. (PSC + UC + Healthy individuals) were compared with the 
transcriptome of: (i) patients with CCA from The Cancer Genome Atlas TCGA (n = 36) and 
“Copenhagen” (n = 217) cohorts, (ii) CCA cells (EGI1 and TFK1) and cell-derived EVs compared to 
their respective control groups, further selecting the ones that are commonly expressed. Heatmap of 
the differentially expressed transcripts in (A) TCGA (left) and “Copenhagen” cohorts (right); (B) 
Whole-cell extracts from CCA cells and normal human cholangiocytes (NHCs); (C) Cell-derived EVs; 
(D) Gene ontology (GO: FunRich database [27]) analysis of the 105 transcripts commonly altered in 
serum EVs, CCA human tumors, CCA cells and in cell-derived EVs, highlighting the biological 
processes and pathways in which the identified transcripts are involved, as well as their biological 
function. Abbreviations: EVs, extracellular vesicles; NHC, normal human cholangiocyte; SL, 
surrounding liver; TCGA, The cancer genome atlas. 
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In order to evaluate the role of these transcripts in carcinogenesis, we conducted a GO analysis 
and observed that, in resemblance with what we previously found in serum EVs, these mRNA 
transcripts code for proteins that are predominantly related with tumor development and 
progression, namely metabolic pathways (nucleic acids and protein metabolism), signal 
transduction, cell communication, EMT and immune response. Although less represented, some 
transcripts were also linked to energy and cell growth/maintenance pathways (Figure 8D). In this 
regard, the transcripts ubiquitin conjugating enzyme E2 C (UBE2C) and serine protease inhibitor B1 
(SERPINB1) arose as potential liquid biopsy biomarkers, being increased in urine EVs isolated from 
patients with CCA in comparison to a group containing patients with PSC, UC and healthy controls 
(Figure 9A,B). Combining these urine biomarkers into one panel increased their diagnostic accuracy, 
providing an AUC value of 0.812 for the diagnosis of CCA (Figure 9C). Noteworthy, the expression 
levels of these transcripts were also markedly upregulated in CCA tumor samples from the TCGA 
and Copenhagen cohorts, when compared with both normal surrounding liver specimens and/or 
normal intrahepatic bile ducts, presenting also increased expression in CCA cells and in CCA-derived 
EVs, when compared with NHCs (Figure 9A,B). Importantly, SERPINB1 mRNA levels increased with 
disease severity in the Copenhagen cohort, being particularly overexpressed in advanced tumor 
stages compared with early stage CCAs (Supplementary Figure 5A). Furthermore, although not 
being presented as one of the best liquid biopsy candidate, Tctex1 domain containing 2 (TCTEX1D2) 
levels were found upregulated in poorly-differentiated tumors compared with well-differentiated 
ones (Supplementary Figure 5B). 
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Figure 9. Potential urine liquid biopsy markers for CCA. From the 39 transcripts commonly found in 
serum EVs and differentially expressed in patient samples, CCA cells and in cell line-derived EVs, 2 
potential urine liquid biopsy markers with the best diagnostic capacity were selected. Box plot 
diagrams with the mRNA transcript abundance in urine EVs (left) and the expression in the TCGA 
and “Copenhagen” cohorts, cholangiocyte cell lines and cell line-derived EVs (right) for (A) Ubiquitin 
conjugatin enzyme E2 C (UBE2C) and (B) Serine proteinase inhibitor B1 (SERPINB1). (C) Diagnostic 
prediction (ROC curves and AUC values) of the selected urine liquid biopsy markers and from the 
combination of UBE2C and SERPINB1 for the diagnosis of CCA in comparison with (PSC + UC + 
Healthy individuals). Abbreviations: AUC, area under the receiver operating characteristic curve; EVs, 
extracellular vesicles; NHC, normal human cholangiocyte; NBD, normal bile ducts; SL, surrounding 
liver; TCGA, The cancer genome atlas. 
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4. Discussion 
In the last decade, a considerable effort has been made to identify novel non-invasive biomarkers 
for the early and accurate diagnosis of CCA [7]. Here, we report for the first time the differential RNA 
profile of serum and urine EVs from patients with CCA, PSC, or UC, and healthy individuals, 
identifying new potential biomarkers with high diagnostic capacity. Noteworthy, some of the altered 
mRNAs were similarly changed in CCA tumors from two independent cohorts of patients, and in 
tumor cells and CCA-derived EVs in vitro, highlighting their utility as liquid biopsy biomarkers as 
well as their potential value as targets for therapy. 
High-throughput omic approaches have been of great help in order to find potential new 
candidate biomarkers. In fact, the identification of the proteomic content of EVs, as well as certain 
circulating proteins, in biofluids have already provided candidate biomarkers in bile, serum, and 
urine from patients with CCA [18,30–32]. We have recently described the differential proteomic 
profiles of serum EVs from patients with CCA, compared to HCC, PSC, and healthy individuals, 
reporting new potential protein biomarkers with high diagnostic capacity [18] that must be 
internationally validated by ELISA technology. Nevertheless, a full transcriptomic analysis in distinct 
body fluids (in particular EVs) from these patients has never been conducted and might result in the 
identification of novel, accurate biomarkers for the diagnosis of CCA. Although proteins are usually 
more stable than mRNAs, their presence within EVs provides them protection from degradation; 
moreover, RNAs are usually easier to detect and quantify, even when found at very low levels, which 
may help in their faster translation into the clinic [33]. In fact, circulating small ncRNAs are found in 
all biofluids (including serum and urine), mainly due to their remarkable resistance to RNase 
degradation. High circulating RNase levels contribute to a low abundance of other types of RNAs 
(mRNAs) and significantly compromise their easy and reliable detection [34]. Still, specific RNAs can 
be released from cancer cells into biofluids, allowing their identification and further determination 
of their potential value as biomarkers, as they may mirror the cellular state within the concept of 
liquid biopsy. For instance, some RNA transcripts were already evidenced and found increased in 
plasma, as is the case of telomerase reverse transcriptase (hTERT) that showed diagnostic and prognostic 
value for prostate cancer, being a good predictor of recurrence [35,36]. Similarly, the levels of the long 
non-coding RNA prostate cancer associated 3 (PCA3) were abundantly found in urine of patients with 
prostate cancer, constituting a promising non-invasive biomarker for the diagnosis of that cancer 
[37,38]. The levels of several miRNAs were also reported altered in serum, plasma, and urine of 
patients with gastrointestinal cancers, including CCA, constituting also potential novel biomarkers 
for cancer diagnosis [7,33,39–41]. 
Taking advantage from our previously reported EV isolation protocol [18], we have here also 
settled up the protocol for the isolation of urine EVs. By analyzing the transcriptomic profile of serum 
and urine EVs from patients with CCA, the present study was pioneer in identifying novel potential 
RNA biomarkers with high diagnostic capacity for CCA. Noteworthy, some of these new RNA 
biomarkers were also significantly altered in CCA tissue from the two international cohorts of 
patients and further disturbed in CCA cell lines and in EVs secreted from these tumor cell lines, when 
compared with NHCs. Consequently, these biomarkers are mirroring what is happening in the tumor 
tissue, since the disturbances observed in tumor biopsies (and CCA cell lines) that are later secreted 
in EVs and released into the bloodstream are amenable for detection either in serum or urine (Figure 
10). This constitutes a novel and innovative liquid biopsy approach where we are able to detect 
specific alterations that are observed in tumor tissue without obtaining tumor samples, harboring a 
high diagnostic value. In the future, evaluating the relevance of these biomarkers in predicting 
prognosis and in guiding therapeutic decisions is envisioned. 
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Figure 10. Novel liquid biopsy approach for cholangiocarcinoma. CCA tumor cells display distinct 
RNA expression profiles which are later released into circulation in EVs, containing potential 
biomarkers for CCA, that are amenable for detection in serum and urine, thus constituting a novel 
liquid biopsy approach. 
Taking into consideration the 105 potential liquid biopsy biomarkers that were identified in 
serum, we herein reported the best five serum biomarkers that display excellent diagnostic accuracy: 
CMIP, GAD1, NME1, CDS1, and CKS1B. Importantly, these novel potential biomarkers might 
constitute better CCA biomarkers than CA19-9 since the AUC values that we herein obtained (up to 
0.891) are higher than the diagnostic capacity reported in a systematic review and a meta-analysis, in 
which the AUC value for CA19-9 was 0.830 [42]. Despite the potential diagnostic value of these 
transcripts, considering that they are concomitantly increased in tumor tissue in two international 
independent cohorts, we postulate that they also might play a pivotal pathological role during 
cholangiocarcinogenesis. Still, no studies have currently addressed the involvement of these 
biomolecules in CCA, although several works already valued their role in other types of cancer. For 
instance, the transcription factor CMIP was previously shown to be increased in human gastric cancer 
and glioma tumors, contributing to tumor proliferation and metastasis [43,44]. Furthermore, high 
CMIP levels were associated with worse prognosis (recurrence-free and overall survival) in gastric 
and breast cancers [43,45] and were related with herceptin resistance in HER2-positive gastric cancer 
cells [46]. Similarly, the enzyme encoded by GAD1 gene, which catalyzes the conversion of L-
glutamic acid to γ-aminobutyric acid, has been found overexpressed in several types of tumors, 
including lung adenocarcinoma [47], nasopharyngeal carcinoma [48], oral squamous cell carcinoma 
[49], prostate cancer [50], and brain metastasis [51], being also found upregulated in colon and HCC 
cells in vitro [52]. In parallel, high GAD1 levels were also shown to correlate with the pathological 
stage of patients with lung adenocarcinoma, positively correlating with metastasis and with worse 
recurrence-free survival [47]. Regarding NME1, its relevance in cancer is still controversial. A meta-
analysis evaluated the prognostic value of NME1 in patients with digestive system neoplasms 
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(including patients with HCC and gallbladder cancer, but not CCA) and reported that high NME1 
levels are correlated with well-differentiated tumors and with less-severe cancer stages, with no 
evident correlation with prognosis [53]. In agreement with the reported metastasis-suppressing role 
of NME1, patients with HCC presenting lower protein levels of NME1 displayed increased 
metastatization [54]. In patients with HCC [55] and in two animal models of HCC [56], NME1 
expression was found upregulated in comparison with non-tumor tissue, while knocking-out NME1 
resulted in an increased number of lung metastasis [56]. Still, increased levels of NME1 negatively 
correlated with disease stage while NME1 upregulation was positively correlated with poor overall 
survival and with higher recurrence [55]. Furthermore, in melanoma patients, a NME1-related gene 
expression signature was reported and linked with increased overall survival [57], pinpointing for a 
potential tumor suppressor role, but new pro-oncogenic roles, mainly related with the expansion of 
stem-like features and tumor growth, were recently reported [58]. Considering CDS1, a DNA 
damage-related function is well-known [59,60] and a screening of several cancer cell lines highlighted 
that the expression levels of CDS1 are dependent on p53 activity, being inversely correlated with the 
presence of a functional p53 [61]. Although CDS1 is thought to act as a tumor suppressor, there is no 
much information in this field. For instance, CDS1 was shown to be decreased in patients with HCC, 
likely as a result of promoter hypermethylation [62]. Nevertheless, its relevance for hepato- and/or 
cholangiocarcinogenesis is yet to be unveiled. Additionally, CKS1B represents an oncogene that has 
been reported increased in retinoblastoma, HCC, nasopharyngeal carcinoma and multiple myeloma 
[63–67]. Importantly, CKS1B upregulation has been positively related to increased proliferation, 
migration, angiogenesis, invasion and chemoresistance, being further related with lymph node 
metastasis and worse prognosis. Overall, regarding these genes, although nothing is still reported in 
CCA pathogenesis, they potentially constitute new key carcinogenic players that deserve further 
attention in the near future. 
Considering the potential urine liquid biopsy biomarkers, we herein were able to report 39 
transcripts that are differentially found in EVs from patients with CCA, sharing their pattern of 
expression in CCA patients from the TCGA and Copenhagen cohorts and in CCA cells and in CCA-
derived EVs in vitro. In fact, this number of transcripts corresponds to almost one-third of the 
identified serum liquid biopsy biomarkers, which might indicate that serum constitutes a richer 
source of potential CCA biomarkers. In this line, we have to bear in mind that EVs released from 
tumor masses directly enter into the bloodstream and their analysis might better mirror what is 
currently happening in the tumor. Furthermore, glomerular filtration might impact on the detected 
tumor-released EVs, therefore explaining the reduced number of urine liquid biopsy biomarkers. 
Still, urine analysis is considered the less invasive procedure for the diagnosis of cancer so far and 
we here describe some potential new urine biomarkers with good diagnostic values that are also 
altered in tumor samples. For instance, UBE2C is commonly upregulated in intestinal-type gastric 
cancer, ovarian cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, 
HCC, and non-small cell lung cancer [68–74]. Remarkably, increased UBE2C expression promotes 
chromosomal instability, cell cycle progression, proliferation and EMT, being positively correlated 
with worse clinical outcomes, mainly overall survival, lymph node metastasis, and progression-free 
survival. Of note, experimental inhibition of UBE2C suppressed the malignant phenotypes, 
surpassing cisplatin resistance in ovarian and non-small cell lung cancers [69,74], in parallel with 
overcoming sorafenib resistance in HCC [73]. On the other hand, the reports regarding SERPINB1 
are still controversial. SERPINB1 levels were found decreased in patients with prostate cancer, 
glioma, and HCC, favoring migration and invasion [75–77], while displaying increased expression in 
cells and patients with oral cancer, correlating with high motility and cell migration in vitro [78]. 
Importantly, SERPINB1 levels were shown to predict the outcome of cisplatin-based chemotherapies 
in melanoma [79] and the value of this transcript/protein as surrogate marker for CCA should be 
evaluated in the future.  
Besides identifying novel CCA biomarkers, we were also able to identify novel potential RNA 
transcripts for the differential diagnosis of CCA vs. PSC. Distinguishing between PSC-associated 
benign biliary strictures and early-stage CCA lesions is challenging. In fact, magnetic resonance 
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imaging (MRI) has a limited resolution for this differential diagnosis [5,80] and performing 
conventional cytology and/or fluorescence in situ hybridization (FISH) after invasive biliary brushing 
by endoscopic retrograde cholangiography only display a moderate diagnostic accuracy and increase 
the odds for procedure-related complications, including pancreatitis and cholangitis [5,80]. In fact, 
several serum and urine EV transcripts provided the maximum diagnostic capacity for the 
differential diagnosis of CCA and PSC, constituting potential biomarkers for the early diagnosis of 
CCA in patients with PSC. Although this work was mainly focused on the study of mRNA 
transcripts, several ncRNAs stood out as novel potential diagnostic biomarkers for the diagnosis of 
CCA. In particular, the levels of the lncRNA MALAT1 are increased in serum EVs from patients with 
CCA compared to PSC, displaying an AUC value of 1.00. In this regard, MALAT1 was found 
upregulated in HCC, contributing to tumor development and progression [81–84], as well as 
identified in HCC-derived exosomes [85]. MALAT1 is also increased in colon cancer cells, directly 
binding to miR-663a, thus acting as a competing endogenous lncRNA; as a result, important cancer-
related miR-663a targets (TGFB1, PIK3CD, P21, JunB, and JunD) were affected [86]. These results 
encourage future studies on the potential role of MALAT1 in CCA. In addition, increased levels of 
miR-604 and miR-551B in serum EVs from patients with CCA also provided excellent diagnostic 
capacities (up to 0.944) for CCA and some studies already started to evaluate their involvement in 
carcinogenesis and as diagnostic biomarkers [87–90]. Considering the high resistance of small 
ncRNAs to RNase degradation, additional efforts should be employed in order to validate their 
diagnostic accuracy.  
Overall, here we reported for the first time the differential RNA profiles of serum and urine EVs 
of patients with CCA, PSC, or UC, compared to healthy individuals, identifying novel non-invasive 
accurate biomarkers for CCA that mirror their expression in tumor tissue, thus constituting a novel 
liquid biopsy approach. The newly identified RNA biomarkers might markedly facilitate the 
diagnosis of these diseases and should be taken into consideration in future studies. These results 
pave the path not only for the discovery of new biomarkers but also for new potential therapeutic 
targets, as they may participate in disease pathogenesis. However, these results need to be now 
validated in large, international, and well-characterized cohorts of patients (and also including 
patients with CCA on a PSC background), in order to ascertain the diagnostic accuracy of the 
proposed biomarkers and then translate our findings into clinics. More importantly, it is pivotal to 
validate these results with easy transferable techniques [e.g., quantitative PCR (qPCR) and droplet 
digital PCR (ddPCR), among others], in order to avoid the time-consuming steps and equipment 
demands for EVs isolation. In this way, we will be a little bit closer to see the use of accurate non-
invasive diagnostic biomarkers for CCA at the clinics.  
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